Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanæs MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Børve M, Dalen TS, Öjlert ÅK, Helland Å (2025)
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Front Oncol, 15, 1681420
DOI 10.3389/fonc.2025.1681420, PubMed 41199847

Førde D, Kilvær T, Pedersen MI, Lombardi AP, D'arsiè I, Paulsen EE, Busund LR, Rakaee M, Dønnem T, Andersen S (2025)
Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status
Front Oncol, 15, 1606933
DOI 10.3389/fonc.2025.1606933, PubMed 41079079

Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B et al. (2025)
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
J Immunother Cancer, 13 (10)
DOI 10.1136/jitc-2024-010975, PubMed 41052886